Treatment-induced changes in the androgen receptor axis: Liquid biopsies as diagnostic/prognostic tools for prostate cancer

Mol Cell Endocrinol. 2018 Feb 15;462(Pt A):56-63. doi: 10.1016/j.mce.2017.08.020. Epub 2017 Sep 4.

Abstract

Prostate cancer progression and treatment relapse is associated with changes in the androgen receptor axis, and analysis of alternations of androgen receptor signaling is valuable for prognostics and treatment optimization. The profile of androgen receptor axis is currently obtained from biopsy specimens, which are not always easy to obtain. Moreover, the information acquired only provides a snapshot of the tumor biology, with strict spatial and temporal limitations. On the other hand, circulation is easily accessible source of both circulating tumor cells and circulating tumor DNA, which can be sampled at numerous time points. This Review will explore the potential use of androgen receptor axis alternations detectable in the blood in therapeutic decision-making and precision medicine for advancing metastatic castration-resistant prostate cancer.

Keywords: Androgen receptor; CTC; Liquid biopsy; Prostate cancer; cfDNA; ctDNA.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Gene Dosage
  • Humans
  • Liquid Biopsy / methods*
  • Male
  • Molecular Targeted Therapy
  • Prognosis
  • Prostatic Neoplasms / blood
  • Prostatic Neoplasms / diagnosis*
  • Prostatic Neoplasms / genetics*
  • Prostatic Neoplasms / therapy
  • Receptors, Androgen / blood
  • Receptors, Androgen / chemistry
  • Receptors, Androgen / genetics
  • Receptors, Androgen / metabolism*

Substances

  • Receptors, Androgen